PrimaryLogo_Mango-05.png
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
03. Oktober 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
Global GLP-1 Receptor Agonist Market
Global GLP-1 Receptor Agonist (Ozempic, Rybelsus, Trulicity, Saxenda, Wegovy, Victoza, Mounjaro, Zepbound) Market Analysis Report 2024-2030 Featuring Eli Lilly and C, Sanofi, Novo Nordisk, AstraZeneca
17. Juli 2024 07:43 ET | Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Global GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Type 2...
22157.jpg
GLP-1 Receptor Agonist Market on the Rise with Anticipated Surge to $16.82 Billion by 2028
29. Januar 2024 10:48 ET | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global market for GLP-1 receptor...
1ProLynx LOGO.png
ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye
29. August 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for...
1ProLynx LOGO.png
ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
03. April 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...
1ProLynx LOGO.png
ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
25. September 2017 09:00 ET | ProLynx LLC
SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control...